Expert Interview
Discussing the different therapeutic approaches from Fulcrum Therapeutics and Arrowhead Pharmaceuticals for the treatment of Facioscapulohumeral muscular dystrophy (FSHD)
Ticker(s): ARWR, RNA, FULCInstitution: University of Washington
- Associate Professor of Neurology at University of Washington and a researcher at the Seattle Wellstone Center.
- Manages ~15 patients with myotonic dystrophy type 1 (DM1).
- Researches focuses on inclusion body myositis, facioscapulohumeral muscular dystrophy, and ALS (funded throug the NIH), and clinical interests focus on neuromuscular disorders, such as motor neuron disease (ALS), myasthenia gravis, peripheral neuropathies and muscular dystrophies including FSHD.
How many FSHD patients do you treat?
Added By: ben_adminWhat are your opinions of Losmapimod?
Added By: ben_adminWhat do you think about the potential of ARO-DUX4?
Added By: ben_adminCompare and contrast the different treatment approached of ARO-DUX4 and Losmapimod. Do you think one is more likely to be successful than the other?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
